Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United States.

The gene therapy BBM-H901 (dalnacogene ponparvovec) has been approved in China for adults with moderate to severe hemophilia ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood product specialist remains hopeful that Hemgenix is here to stay. “I hope ...

New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis.

Columnist Jennifer Lynne shares her takeaways from the NOW Conference, which brought together people with VWD and other bleeding disorders.

China has approved its first gene therapy for hemophilia B, an inherited bleeding disorder caused by the deficiency of the clotting protein factor IX (FIX).

H901, has been officially approved by the National Medical Products Administration for the treatment of adult patients with moderate to severe hemophilia B.

Belief BioMed and Takeda China today jointly announced that BBM-H901, has been officially approved by the National Medical ...

This innovative injection was developed and produced by Belief BioMed, while Takeda China is responsible for its ...

More than 40% of the 225 scientists and public health workers at the CDC's National Center on Birth Defects and Developmental ...

To my surprise — and like reviewers who call the tool the best $10 they’ve ever spent — the Bug Bite Thing lived up to the ...

The Chile immunohematology market, valued at US$ 11.59 million in 2023, is projected to experience significant growth over the next decade, with an expected market valuation of US$ 17.32 million by ...